Abivax nears $11 billion valuation after fundraising eases M&A pressure

Abivax SA raised $800 million in an expanded share sale, valuing the company at nearly $11 billion, after strong investor demand. The proceeds eased pressure to pursue a near-term sale, reducing M&A uncertainty. The fundraising strength is a positive read-through for capital access and balance-sheet runway.

Analysis

Abivax SA raised $800 million in an expanded share sale, valuing the company at nearly $11 billion, after strong investor demand. The proceeds eased pressure to pursue a near-term sale, reducing M&A uncertainty. The fundraising strength is a positive read-through for capital access and balance-sheet runway.